A Phase II Study of PT2385 for Patients with Recurrent Glioblastoma

Full Title

Single-arm, Open-label Phase II Efficacy Study of First-in-class HIF2-Alpha Inhibitor, PT2385, for Patients with Recurrent Glioblastoma (ABTC 1602)


In this study, researchers are evaluating the safety and effectiveness of an investigational drug called PT2385 in patients with glioblastoma that has come back despite prior treatment. PT2385 works by targeting a signaling pathway that controls the production of several proteins that help glioma cells recover, multiply, and potentially develop resistance to common therapies. It is a tablet that is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must be experiencing a first relapse of glioblastoma following radiation therapy and chemotherapy (temozolomide).
  • Patients must recover from the serious side effects of previous therapies before entering the study.
  • Patients must be able to undergo contrast-enhanced MRI.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Anna Piotrowski at 212-639-5586.





Disease Status

Relapsed or Refractory